Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer

NCT00128596 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00128596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer
Lead sponsor
University of Pittsburgh
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
Not reported
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer